PMID- 30138480
OWN - NLM
STAT- MEDLINE
DCOM- 20190207
LR  - 20190215
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 8
DP  - 2018
TI  - Serum matrix metalloproteinase 3 levels are associated with an effect of 
      iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid 
      arthritis.
PG  - e0202601
LID - 10.1371/journal.pone.0202601 [doi]
LID - e0202601
AB  - OBJECTIVE: The aim of this study was to clarify whether serum matrix 
      metalloproteinase 3 (MMP-3) levels are associated with an effect of iguratimod as 
      add-on therapy to biological DMARDs (bDMARDs) in patients with rheumatoid 
      arthritis (RA). METHODS: Forty three patients with RA were treated with 
      iguratimod as add-on therapy to bDMARDs. They were classified into remission and 
      non-remission groups at 24 weeks of iguratimod therapy. Remission was defined as 
      a state with a disease activity score (DAS) <2.6 in 28 joints (termed DAS 
      remission) and total power Doppler ultrasound (US) score <3 (termed US 
      remission). The serum MMP-3 levels at baseline and at 12 weeks were compared 
      between these two groups. RESULTS: There were no significant differences in the 
      serum MMP-3 levels at baseline between the DAS and US remission groups and the 
      non-remission group. The serum MMP-3 levels at 12 weeks in the US remission group 
      were significantly lower than those in the non-remission group. The ratios of the 
      serum MMP-3 levels at baseline to those at 12 weeks in both the DAS and US 
      remission groups were significantly lower than those in the non-remission group. 
      An MMP-3 ratio <0.86 was determined as the cut-off value to predict US remission 
      at 24 weeks. CONCLUSION: Our findings suggest that the ratios of the serum MMP-3 
      levels at baseline to those at 12 weeks could be used to predict remission in RA 
      patients who are administered iguratimod as an add-on to bDMARDs.
FAU - Tokai, Nao
AU  - Tokai N
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Yoshida, Shuzo
AU  - Yoshida S
AD  - Department of Internal Medicine, Arisawa General Hospital, Hirakata, Osaka, 
      Japan.
FAU - Kotani, Takuya
AU  - Kotani T
AUID- ORCID: 0000-0003-2190-0780
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Yoshikawa, Ayaka
AU  - Yoshikawa A
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Kimura, Yuko
AU  - Kimura Y
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Fujiki, Youhei
AU  - Fujiki Y
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Matsumura, Yoko
AU  - Matsumura Y
AD  - Central Laboratory, Osaka Medical College, Takatsuki, Osaka, Japan.
FAU - Takeuchi, Tohru
AU  - Takeuchi T
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Makino, Shigeki
AU  - Makino S
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
FAU - Arawaka, Shigeki
AU  - Arawaka S
AD  - Department of Internal Medicine (IV), Osaka Medical College, Takatsuki, Osaka, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20180823
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Chromones)
RN  - 0 (Sulfonamides)
RN  - 4IHY34Y2NV (iguratimod)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
EIN - PLoS One. 2019 Jan 30;14(1):e0211750. PMID: 30699195
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*administration & dosage/adverse effects
MH  - Arthritis, Rheumatoid/*drug therapy/genetics/physiopathology
MH  - Chromones/*administration & dosage/adverse effects
MH  - Female
MH  - Genetic Association Studies
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*genetics
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Sulfonamides/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC6107217
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/08/24 06:00
MHDA- 2019/02/08 06:00
PMCR- 2018/08/23
CRDT- 2018/08/24 06:00
PHST- 2018/06/19 00:00 [received]
PHST- 2018/08/06 00:00 [accepted]
PHST- 2018/08/24 06:00 [entrez]
PHST- 2018/08/24 06:00 [pubmed]
PHST- 2019/02/08 06:00 [medline]
PHST- 2018/08/23 00:00 [pmc-release]
AID - PONE-D-18-18264 [pii]
AID - 10.1371/journal.pone.0202601 [doi]
PST - epublish
SO  - PLoS One. 2018 Aug 23;13(8):e0202601. doi: 10.1371/journal.pone.0202601. 
      eCollection 2018.